Acute hereditary coproporphyria induced by the androgenic/anabolic steroid methandrostenolone (Dianabol)

Lane, Peter R.; Massey, Kenneth L.; Worobetz, Lawrence; Jutras, Michel Norbert; Hull, Peter

doi:10.1016/s0190-9622(94)70029-x

Cited by 12 publications

(8 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Facial vesicles and bullae on the dorsal aspects of the hands developed in a previously asymptomatic weightlifter who began to use AASs. His skin photosensitivity resolved following the discontinuation of AASs 29 …”

Section: Cutaneous Conditions Exacerbated By Aassmentioning

confidence: 99%

Cutaneous manifestations of anabolic–androgenic steroid use in athletes

Walker¹,

Adams²

2009

Int J Dermatology

View full text Add to dashboard Cite

Increased public awareness of the performance-enhancing benefits of anabolic-androgenic steroids (AASs) in athletes has resulted from the media coverage of the BALCO scandal and Mitchell report. The impact of this increased notoriety on the consumption of these drugs remains unclear, however. In addition, the negative connotation associated with the use of AASs may make users less forthcoming when interacting with their physicians. Cutaneous manifestations develop early in the use of AASs, placing dermatologists in a unique position to make an early diagnosis of AAS abuse in patients who engage in competitive sports. This review of the literature focuses on dermatologic presentations of AAS use.

show abstract

Section: Cutaneous Conditions Exacerbated By Aassmentioning

confidence: 99%

Cutaneous manifestations of anabolic–androgenic steroid use in athletes

Walker¹,

Adams²

2009

Int J Dermatology

View full text Add to dashboard Cite

show abstract

“…Exacerbation of other skin diseases such as hereditary coproporphyria, linear keloids and psoriasis has been reported as side effects of AAS [10–12]. Therapeutic applications of AAS in dermatology include long‐term prophylaxis of hereditary angioedema (danazol, stanozolol), treating cryofibrinogenemia, use of anticatabolic effects in burns and extensive wounds and in wasting syndrome in advanced HIV infection [13–19].…”

Section: Introductionmentioning

confidence: 99%

Abuse of anabolic‐androgenic steroids and bodybuilding acne: an underestimated health problem

Melnik

Jansen²,

Grabbe³

2007

J Deutsche Derma Gesell

118

View full text Add to dashboard Cite

Abuse of anabolic-androgenic steroids (AAS) by members of fitness centers and others in Germany has reached alarming dimensions. The health care system provides the illegal AAS to 48.1 % of abusers. Physicians are involved in illegal prescription of AAS and monitoring of 32.1 % of AAS abusers. Besides health-threatening cardiovascular, hepatotoxic and psychiatric long-term side effects of AAS, acne occurs in about 50 % of AAS abusers and is an important clinical indicator of AAS abuse, especially in young men 18-26 years of age. Both acne conglobata and acne fulminans can be induced by AAS abuse. The dermatologist should recognize bodybuilding acne, address the AAS abuse, and warn the patient about other potential hazards.

show abstract

“…Inhibition of the gonadotropin secretion stabilizes the endogenous steroid production at a low level. Others report that the application of hormonal oral contraceptives or an androgenic, anabolic steroid can lead to the clinical manifestation of acute intermittent porphyria (Wetterberg 1964;Brinkmann, Hardinghaus, Wimmer and Junge-Hulsing 1979), variegate porphyria (McKenzie and Acharya 1972), or hereditary coproporphyria (Lane, Massey, Worobetz, Jutras and Hull 1994). These symptoms have been thought to be caused by progesterone, estrogen or similar steroids, because these hormones increase laminolevulinic acid synthase in man or chick embryo (Anderson, Freddarct and Kappas 1982;Thompson, Small, Lowe, Forbes, Park, Scobie and Brodie 1984).…”

Section: Discussionmentioning

confidence: 99%

Hormonal Oral Contraceptives, Urinary Porphyrin Excretion and Porphyrias

Groß

Daume

et al. 1995

Horm Metab Res

View full text Add to dashboard Cite

The influence of hormonal oral contraceptives on the urinary porphyrin excretion of 40 healthy females has been studied. Two different hormonal oral contraceptives (combinations of gestoden or desogestrel, respectively, and ethinylestradiol) were applied for half a year. In each case twenty women received one of these two combinations. Porphyrin precursors delta-aminolevulinic acid and porphobilinogen were normal in all subjects as well as the mean of uroporphyrin and coproporphyrin. One healthy female developed a mild secondary coproporphyrinuria. In this case coproporphyrin isomer I was slightly enhanced and isomer III slightly lowered. Furthermore it could be shown that three females with repeated premenstrual clinical expression of an acute hepatic porphyria (acute intermittent porphyria and hereditary coproporphyria) could be treated successfully with a hormonal oral contraceptive or other exogenous hormones to stabilize the latent, subclinical phase of the disease.

show abstract

Acute hereditary coproporphyria induced by the androgenic/anabolic steroid methandrostenolone (Dianabol)

Cited by 12 publications

References 19 publications

Cutaneous manifestations of anabolic–androgenic steroid use in athletes

Cutaneous manifestations of anabolic–androgenic steroid use in athletes

Abuse of anabolic‐androgenic steroids and bodybuilding acne: an underestimated health problem

Hormonal Oral Contraceptives, Urinary Porphyrin Excretion and Porphyrias

Contact Info

Product

Resources

About